Stimulation med 0,3 mg rekombinant human thyrotropin øger effekten af 131 I-behandling hos patienter med atoksisk nodulær struma: En prospektiv, randomiseret, dobbeltblindet undersøgelse - sekundærpublikation

Translated title of the contribution: Stimulation with 0,3 mg recombinant human thyrotropin (rhTSH) increases the effect of 131I therapy in patients with nontoxic nodular goiter. A prospective, randomized, double-blind trial--secondary publication

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

In a randomized, double-blind, placebo-controlled trial, 57 patients with nontoxic nodular goiter were stimulated with either 0.3 mg recombinant human thyrotropin (rhTSH) or placebo before radioactive iodine 131I therapy. After one year the goiter reduction had improved by 35% compared to conventional 131I therapy. The difference was most pronounced in patients with a large goiter. Adverse effects, including development of permanent hypothyroidism, were significantly more frequent in the rhTSH group. Patient satisfaction was high and uninfluenced by the use of rhTSH.
Udgivelsesdato: 2006-Nov-20
Translated title of the contributionStimulation with 0,3 mg recombinant human thyrotropin (rhTSH) increases the effect of 131I therapy in patients with nontoxic nodular goiter. A prospective, randomized, double-blind trial--secondary publication
Original languageDanish
JournalUgeskrift for læger
Volume168
Issue number47
Pages (from-to)4098-4101
ISSN0041-5782
Publication statusPublished - 20. Nov 2006

Cite this